BioSight
Companies
Ocugen, Inc. logo

OCGN

NASDAQMALVERN, PA
Ocugen, Inc.

Ocugen develops gene therapies and vaccine platforms for rare eye diseases and respiratory conditions. The company's pipeline includes OCU400 for retinitis pigmentosa and OCU410ST for Stargardt disease, both in clinical trials, along with an inhaled mucosal vaccine platform in earlier development stages. Ocugen requires additional financing to advance these programs through clinical development and regulatory approval.

Price history not yet available for OCGN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar